Privacy-by-design generation of two virtual clinical trials in multiple sclerosis and their release as open datasets
Author:
Affiliation:
1. Nantes Université, INSERM
2. Inserm CIC 1434, University Hospital of Strasbourg
3. Biogen France S.A.S
4. Merck Santé S.A.S
5. Octopize
6. University Hospital of Rennes
Abstract
Sharing information provided by individual patient data is restricted by regulatory frameworks due to privacy concerns. Generative artificial intelligence could generate shareable virtual patient populations, as proxies of sensitive reference datasets. Explicit demonstration of privacy is demanded. Here, we determined whether a privacy-by-design technique called “avatars” can generate synthetic randomized clinical trials (RCTs). We generated 2160 synthetic datasets from two RCTs in multiple sclerosis (NCT00213135 and NCT00906399) with different configurations to select one synthetic dataset with optimal privacy and utility for each. Several privacy metrics were computed, including protection against distance-based membership inference attacks. We assessed utility by comparing variable distributions and checking that all of the endpoints reported in the publications had the same effect directions, were within the reported 95% confidence intervals, and had the same statistical significance. Protection against membership inference attacks was the hardest privacy metric to optimize, but the technique yielded robust privacy and replication of the primary endpoints. With optimized generation configurations, we could select one dataset from each RCT replicating all efficacy endpoints of the placebo and commercial treatment arms with a satisfying privacy. To show the potential to unlock health data sharing, we released both placebo arms as open datasets.
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials;Kappos L;JAMA Neurol.,2020
2. Big data in MS—What can we learn from large international observational studies such as MSBase?;Warnke C;Mult. Scler. J.,2020
3. No head-to-head trial? simulate the missing arms;Caro JJ;PharmacoEconomics,2010
4. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research;Signorovitch JE;Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res.,2012
5. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder;Pittock SJ;Ann. Neurol.,2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3